Pancreatic Cancer Clinical Trials 2024

Pancreatic Cancer Clinical Trials 2024

Pancreatic Cancer research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in pancreatic cancer clinical trials today.

Trials for Adenocarcinoma Patients

Trials for Pancreatic Neuroendocrine Tumors Patients

Trials for Metastatic Patients

Trials With No Placebo

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to pancreatic cancer

What are the top hospitals conducting pancreatic cancer research?

Pancreatic cancer, a devastating and often challenging disease to treat, has led some hospitals to the forefront of groundbreaking clinical trials. At Memorial Sloan Kettering Cancer Center in New york City, nine active pancreatic cancer trials are currently underway, building upon their impressive portfolio of 44 completed trials since their first recorded investigation in 2006. Similarly, Massachusetts General Hospital in Boston is making significant strides with five ongoing pancreatic cancer trials and an extensive history of 49 previous studies dating back to their inaugural trial in 1998.

Boston's Dana Farber Cancer Institute also contributes to this vital research with five active pancreatic cancer trials and a commendable track record of 27 past investigations since initiating their first trial in collaboration with Memorial Sloan Kettering in 2006. While located away from the major medical hubs, Katmai Oncology Group based in Anchorage has emerged as a key player too. This institute is conducting five current clinical tests for pancreatic cancer while having accomplished twelve earlier groundbreaking experiments since recording its pioneering trial back in 2009.

In Palo Alto, California resides another institution dedicated to advancing knowledge about this challenging form of cancer – the Palo Alto Medical Foundation Health Care. Currently engaged in five active pancreatic cancer trials and contributing significantly towards understanding the disease through eight previously conducted investigations; theirs can be traced back only twelve years ago to when they initiated their first recorded trial on this subject matter during 2009.

These leading hospitals signify hope against all odds by investing time, resources, and expertise into finding novel solutions for patients battling pancreatic cancer worldwide. Their unwavering commitment paves the way for progress toward improved treatments and outcomes that could one day change countless lives affected by this relentless disease

Which are the best cities for pancreatic cancer clinical trials?

When it comes to pancreatic cancer clinical trials, several cities are leading the way in research and development. New york, with its 27 active trials, focuses on treatments such as LY3537982, Piperacillin-tazobactam, and more. Anchorage follows closely behind with 26 ongoing studies that explore options like Fluorouracil and Subprotocol C2 (MET exon 14 deletion/mutation). Los Angeles also stands out with 23 active trials examining therapies like Pazopanib Hydrochloride and Chemotherapy. These cities offer individuals battling pancreatic cancer access to cutting-edge clinical trials that pave the way for advancements in care and hope for better outcomes.

Which are the top treatments for pancreatic cancer being explored in clinical trials?

Pancreatic cancer clinical trials are delving into various treatment options, with some standout contenders taking the lead. Gemcitabine, a well-established player in the field since its listing in 1998, remains at the forefront with two active and an impressive 248 all-time pancreatic cancer trials. Another noteworthy contender is pharmacological studies specifically targeting pancreatic cancer, currently underway in two active trials amidst a total of 15 past investigations since being introduced in 2007. Similarly, gemcitabine hydrochloride has shown promise with two ongoing clinical trials and a history of participation in 21 previous pancreatic cancer studies starting from 2003. Lastly, chemotherapy continues to be explored as an important approach for fighting this challenging disease through two active trials and past involvement in fourteen clinical investigations since its first listing back in 2009. As researchers continue their relentless pursuit for effective treatments against pancreatic cancer, these top contenders offer hope on the horizon.

What are the most recent clinical trials for pancreatic cancer?

Promising advancements in the fight against pancreatic cancer have emerged through recent clinical trials. Noteworthy among them is A2530, a trial that explores new treatment options for this challenging disease. Additionally, SGN-BB228 has shown potential as a therapeutic approach to combat pancreatic cancer. Another avenue of research involves the use of brigimadlin (BI 907828) as an experimental treatment option in Phase 2 trials. Furthermore, PT199 and TC-510 are being evaluated in Phase 1 and Phase 2 trials respectively, offering hope for improved outcomes and increased survival rates for patients battling pancreatic cancer. These ongoing studies mark significant progress toward finding effective treatments to combat this formidable illness.

What pancreatic cancer clinical trials were recently completed?

In recent years, numerous clinical trials have been completed in the quest to improve treatments for pancreatic cancer. Noteworthy among them are a trial investigating Cisplatin sponsored by CanBas Co. Ltd., which concluded in December 2021; a trial testing Dapagliflozin led by Washington University School of Medicine, completed in February 2021; and a Plerixafor study supported by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, finalized in November 2020. These trials highlight the ongoing efforts of researchers to advance our understanding and treatment options for this challenging disease.